Antibody Development for Escherichia Coli

Creative Biolabs provides antibody customization services for Escherichia Coli (E.coli) base on our advanced antibody-related technique platform to boost your Antibody-antibiotic Conjugate (AAC) projects. Our professional scientists have extensive experience in antibody engineering in both research quantities and large scale for industrial applications. We can offer high-quality customized antibody development services by adjusting protocols to meet even the most specific requirements.

E.Coli Introduction

E.coli remains to be one of the most frequent causes of several common bacterial infections in humans, such as enteritis, urinary tract infection, septicemia, and neonatal meningitis. As the most common Gram-negative pathogen in humans, antibiotic resistance in E.coli attracts particular concern. E. coli strains are classified into seven pathogenic types. Among them, typical EnteroHaemorrhagic E.coli (EHEC) strains to produce Shiga-like toxins making them the most virulent diarrhoeagenic E. coli known to date.

Fig.1 Low-temperature electron micrograph of a cluster of E. coli bacteria (10,000x).

Outer Membrane Components

It has been proved that antibodies against certain bacterial surface components are helpful in fighting against severe E.coli infection. E.coli contains a double membrane providing both protection and nutrients for viability. The outer membrane (OM) of E.coli is a unique asymmetric lipid bilayer composed of lipopolysaccharides (LPSs) in the outer leaflet and phospholipids (PLs) in the inner leaflet. There are two classes of OM protein, transmembrane β-barrel proteins (named OMPs) and lipoproteins. OMP contains a host of fully integrated membrane proteins which serve essential functions for the cell, such as nutrient uptake, cell signaling, cell adhesion, and waste export. Chaperones deliver OMPs to the β-barrel assembly machine complex for assembly into the OM. For OMPs, SurA is the most major chaperone in E.coli.

Fig.2 E.coli envelope structure and outer membrane (OM) biogenesis machines. (Grabowicz, 2017)

Antibodies as Therapeutics

Increasing disease burden together with declining potency of traditional antimicrobials has heightened the need for novel therapeutic strategies to combat several diseases caused by E.coli. One possible strategy to improve the current situation is to enhance the host immune response with antibiotic therapy against the multidrug resistance (MDR) pathogen. In fact, a novel therapeutic modality against MDR E.coli. infections has emerged, and anti-MDR E.coli. antibody can be a promising approach for this infection. Moreover, AAC combining an anti-MDR E.coli antibody with a specific antibiotic can be more powerful for E.coli infection therapy.

Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in antibody development services against Escherichia Coli (E.coli) for your AAC development. Please feel free to contact us for more details.

Reference: